Soluble ST2 protein in the short-term prognosis after hospitalisation in chronic systolic heart failure

Kardiologia Polska

Volumn 72, Issue 8, 2014, Pages 725-734

  Wojtczak Soska, Karolina ^a   Sakowicz, Agata ^a   Pietrucha, Tadeusz ^a   Lelonek, Małgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Chronic heart failure; Prognosis; sST2 protein

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; GLUCOSE; HORMONE PRECURSOR; PROTEIN; ST2 PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; COMORBIDITY; DIET RESTRICTION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PROGNOSIS; PROTEIN BLOOD LEVEL; QRS COMPLEX; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SYSTOLIC HEART FAILURE; AGED; BLOOD; CHRONIC DISEASE; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; BIOMARKERS; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; VENTRICULAR FUNCTION, LEFT;

EID: 84906858433     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.a2014.0085     Document Type: Article

References (26)

1. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J, 2008; 29: 2388-2442.
2. Bao Y, Shang X, Zhou L et al. Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome. Arch Med Sci, 2011; 7: 247-256.
3. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Disco, 2008; 7: 827-840.
4. Sanada S, Hakuno D, Higgins LJ et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Incest, 2007; 117: 1538-1549.
5. Ciccone MM, Cortese F, Gesualdo M et al. A novel cardiac bio-marker: ST2: a review. Molecules, 2013; 18: 15314-15328.
6. Sabatine MS, Morrow DA, Higgins LJ et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation, 2008; 117: 1936-1944.
7. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol, 2008; 52: 1458-1465.
8. Shimpo M, Morrow DA, Weinberg EO et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation, 2004; 109: 2186-2190.
9. Mueller T, Dieplinger B, Gegenhuber A et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008; 54: 752-756.
10. Boisot S, Beede J, Isakson S et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail, 2008; 14: 732-738.
11. Bayes-Genis A, Pascual-Figal D, Januzzi JL et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol, 2010; 63: 1171-1178.
12. Manzano-Fernandez S, Mueller T, Pascual-Figal D et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol, 2011; 107: 259-267.
13. Pascual-Figal D, Manzano-Fernandez S, Boronat M et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail, 2011; 13: 718-725.
14. Shah RV, Chen-Tournoux AA, Picard MH et al. Serum levels of the interleukin- 1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail, 2009, 2: 311-319.
15. Ky B, French B, McCloskey K et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail, 2011; 4: 180-187.
16. Weinberg EO, Shimpo M, Hurwitz S et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation, 2003; 107: 721-726.
17. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol, 2009; 54: 2174-2179.
18. Vazquez R, Bayes-Genis A, Cygankiewicz I et al. The MUSIC risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J, 2009; 30: 1088-1096.
19. Bayes-Genis A, de Antonio M, Galán A et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail, 2012; 14: 32-38.
20. Rywik S, Rywik T, Korewicki J. Epidemiologia i etiologia niewydolności serca. In: Podolec P, Jankowska E, Ponikowski P et al. eds. Przewlekła niewydolność serca. Medycyna Praktyczna, Kraków, 2009: 61-71.
21. Young JB. Rokowanie w niewydolności serca. In: Mann DL ed. Niewydolność serca. Wydawnictwo Czelej, Lublin, 2006: 519-536.
22. Miller AM, Purves D, McConnachie A. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS One, 2012; 7: e0047830.
23. Fousteris E, Melidonis A, Panoutsopoulos G et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol, 2011; 10: 101.
24. Wojtczak-Soska K, Pietrucha T, Sakowicz A. Lelonek M. Soluble ST2 protein in chronic heart failure is independent of traditional factors. Arch Med Sci, 2013; 9, 1: 21-26
25. Weir RA, Miller AM, Murphy GE et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol, 2010; 55: 243-250.
26. Lupon J, de Antonio M, Galán A et al. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc, 2013; 88: 234-243